HeraMED Raises $1.98 Million at 4.8% Discount to Fund International Growth
HeraMED Limited has raised $1.98 million through a discounted share placement to fund its digital maternity care platform's commercial growth across the US, Australia, and Europe.
- Raised $1.98 million via placement at 1.2 cents per share
- Placement price set at a 4.8% discount to recent VWAP
- Funds to support commercial rollout of HeraCARE platform internationally
- Strong backing from new and existing institutional investors
- Westar Capital acted as Lead Manager, receiving fees and options
Capital Raise to Fuel International Growth
HeraMED Limited (ASX – HMD), a pioneer in digital maternity care technology, has successfully completed a $1.98 million capital raising through a private placement of 165 million shares at 1.2 cents each. This placement, priced at a modest 4.8% discount to the 15-day volume weighted average price, attracted strong support from both new and existing institutional and sophisticated investors, signaling continued confidence in the company’s strategic direction.
The fresh capital is earmarked to bolster working capital, enabling HeraMED to accelerate the commercial deployment of its flagship maternity care platform, HeraCARE, across key markets including the United States, Australia, and Europe. This move aligns with the company’s ambition to transform prenatal and postpartum care through its integrated hardware and software solutions.
Backing from Institutional Investors and Lead Manager
HeraMED’s Managing Director and CEO, Anoushka Gungadin, expressed optimism about the placement, highlighting the growing market interest in the US and the company’s expanding pipeline of health system partnerships. The capital raise extends HeraMED’s cash runway, providing the financial flexibility to convert these opportunities into tangible outcomes for mothers, clinicians, and shareholders alike.
Westar Capital Limited served as Lead Manager for the placement, securing a 6% capital raising fee and 20 million options exercisable at 2 cents until December 2028. This arrangement underscores the market’s belief in HeraMED’s growth potential and the value of its innovative maternity care ecosystem.
Strategic Implications and Market Positioning
HeraMED’s proprietary platform combines clinically validated in-home fetal and maternal heart rate monitoring with cloud computing, artificial intelligence, and big data analytics. The company’s integrated approach aims to improve accessibility, efficiency, and effectiveness of maternity care, addressing a critical need in healthcare systems worldwide.
By securing this funding, HeraMED positions itself to scale its technology offerings and deepen its footprint in competitive international markets. The placement also reflects a broader investor appetite for digital health solutions that promise to reshape traditional care models.
Looking ahead, the company’s ability to execute on its commercial roadmap and demonstrate measurable outcomes will be key to sustaining investor confidence and driving long-term value creation.
Bottom Line?
HeraMED’s latest capital raise sets the stage for accelerated global expansion, but execution risks remain as it scales its digital maternity care platform.
Questions in the middle?
- How quickly can HeraMED convert its growing pipeline into revenue-generating contracts?
- What impact will the placement have on existing shareholders in terms of dilution?
- How will HeraMED differentiate itself amid increasing competition in digital health?
